These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 7693955

  • 1. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
    Motzer RJ, Mazumdar M, Gulati SC, Bajorin DF, Lyn P, Vlamis V, Bosl GJ.
    J Natl Cancer Inst; 1993 Nov 17; 85(22):1828-35. PubMed ID: 7693955
    [Abstract] [Full Text] [Related]

  • 2. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
    Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V.
    J Clin Oncol; 1997 Jul 17; 15(7):2546-52. PubMed ID: 9215823
    [Abstract] [Full Text] [Related]

  • 3. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity.
    Motzer RJ, Mazumdar M, Bosl GJ, Bajorin DF, Amsterdam A, Vlamis V.
    J Clin Oncol; 1996 Apr 17; 14(4):1098-105. PubMed ID: 8648363
    [Abstract] [Full Text] [Related]

  • 4. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support.
    Broun ER, Nichols CR, Turns M, Williams SD, Loehrer PJ, Roth BJ, Lazarus HM, Einhorn LH.
    Cancer; 1994 Mar 15; 73(6):1716-20. PubMed ID: 7512438
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
    Motzer RJ, Gulati SC, Tong WP, Menendez-Botet C, Lyn P, Mazumdar M, Vlamis V, Lin S, Bosl GJ.
    Cancer Res; 1993 Aug 15; 53(16):3730-5. PubMed ID: 8393380
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Germ cell tumor].
    Kasai M, Kiyama Y.
    Gan To Kagaku Ryoho; 1995 Oct 15; 22(12):1749-55. PubMed ID: 7574805
    [Abstract] [Full Text] [Related]

  • 11. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
    Margolin K, Doroshow JH, Ahn C, Hamasaki V, Leong L, Morgan R, Raschko J, Shibata S, Somlo G, Tetef M.
    J Clin Oncol; 1996 Oct 15; 14(10):2631-7. PubMed ID: 8874321
    [Abstract] [Full Text] [Related]

  • 12. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
    Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R, Bokemeyer C, Schmoll HJ, Huhn D.
    J Clin Oncol; 1994 Jun 15; 12(6):1223-31. PubMed ID: 7911158
    [Abstract] [Full Text] [Related]

  • 13. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients.
    Mencel PJ, Motzer RJ, Mazumdar M, Vlamis V, Bajorin DF, Bosl GJ.
    J Clin Oncol; 1994 Jan 15; 12(1):120-6. PubMed ID: 7505805
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.
    Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, Reich L, Flombaum C, Mariani T, Tong WP, Bosl GJ.
    J Clin Oncol; 2000 Mar 15; 18(6):1173-80. PubMed ID: 10715285
    [Abstract] [Full Text] [Related]

  • 17. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C, German Testicular Cancer Study Group.
    J Clin Oncol; 2003 Nov 15; 21(22):4083-91. PubMed ID: 14568987
    [Abstract] [Full Text] [Related]

  • 18. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
    Horwich A, Sleijfer DT, Fosså SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP.
    J Clin Oncol; 1997 May 15; 15(5):1844-52. PubMed ID: 9164194
    [Abstract] [Full Text] [Related]

  • 19. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
    Bokemeyer C, Köhrmann O, Tischler J, Weissbach L, Räth U, Haupt A, Schöffski P, Harstrick A, Schmoll HJ.
    Ann Oncol; 1996 Dec 15; 7(10):1015-21. PubMed ID: 9037359
    [Abstract] [Full Text] [Related]

  • 20. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
    Lotz JP, André T, Donsimoni R, Firmin C, Bouleuc C, Bonnak H, Merad Z, Esteso A, Gerota J, Izrael V.
    Cancer; 1995 Feb 01; 75(3):874-85. PubMed ID: 7828139
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.